<DOC>
	<DOCNO>NCT02810873</DOCNO>
	<brief_summary>This clinical trial study positron emission tomography image use copper Cu 64 TP3805in patient breast cancer . Diagnostic procedure , positron emission tomography ( PET ) positron emission mammography ( PEM ) scan , use Cu-64-TP3805 may help doctor find diagnose breast cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . The study 's primary goal assess ability Cu-64-TP3805 ( copper Cu 64 TP3805 ) detect primary breast lesion determine F-18-FDG ( fludeoxyglucose F 18 ) scan . II . The study 's second goal determine ability Cu-64-TP3805 detect primary breast lesion determine histology ( sensitivity ) . III . The study 's third goal determine ability Cu-64-TP3805 detect metastatic lesion identify F-18-FDG whole-body scan . OUTLINE : This dose-finding 2-stage study . STAGE I : Patients positive biopsy abnormal ( positive ) fludeoxyglucose F18-labeled PET whole-body scan undergo whole-body copper Cu 64 TP3805-labeled PET scan . STAGE II : Patients positive biopsy , fludeoxyglucose F18 scan undergo breast fludeoxyglucose F18-labeled PEM scan follow breast copper Cu 64 TP3805-labeled PEM scan .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Female Breast cancer show abnormal mammogram histology verification ( stage1 patient also need positive F18FDG wholebody scan ) Tumor mass 1 cm large , determine mammography , ultrasound , magnetic resonance imaging ( MRI ) Signed informed consent form approve institutional review board ( IRB ) Pregnant lactate female Patient asthma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>